Follow
Shravan Kumar Sriraman
Shravan Kumar Sriraman
PhD, Pharmaceutical Science
Verified email at husky.neu.edu
Title
Cited by
Cited by
Year
Barriers to drug delivery in solid tumors
SK Sriraman, B Aryasomayajula, VP Torchilin
Tissue barriers 2 (3), 2014
3552014
Anti-cancer activity of doxorubicin-loaded liposomes co-modified with transferrin and folic acid
SK Sriraman, G Salzano, C Sarisozen, V Torchilin
European Journal of Pharmaceutics and Biopharmaceutics 105, 40-49, 2016
1282016
Polyethyleneimine-lipid conjugate-based pH-sensitive micellar carrier for gene delivery
RR Sawant, SK Sriraman, G Navarro, S Biswas, RA Dalvi, VP Torchilin
Biomaterials 33 (15), 3942-3951, 2012
1262012
Reversal of chemoresistance in ovarian cancer by co-delivery of a P-glycoprotein inhibitor and paclitaxel in a liposomal platform
Y Zhang, SK Sriraman, HA Kenny, E Luther, V Torchilin, E Lengyel
Molecular Cancer Therapeutics 15 (10), 2282-2293, 2016
792016
Ceramide limits phosphatidylinositol-3-kinase C2β-controlled cell motility in ovarian cancer: potential of ceramide as a metastasis-suppressor lipid
K Kitatani, T Usui, SK Sriraman, M Toyoshima, M Ishibashi, S Shigeta, ...
Oncogene 35 (21), 2801-2812, 2016
612016
Enhanced Cytotoxicity of Folic Acid-Targeted Liposomes Co-Loaded with C6 Ceramide and Doxorubicin: In Vitro Evaluation on HeLa, A2780-ADR, and H69-AR Cells
SK Sriraman, J Pan, C Sarisozen, E Luther, V Torchilin
Molecular pharmaceutics 13 (2), 428-437, 2016
592016
Recent Advances with Liposomes as Drug Carriers
SK Sriraman, VP Torchilin
Advanced Biomaterials and Biodevices, 79-119, 2014
432014
Cytotoxicity of PEGylated liposomes co-loaded with novel pro-apoptotic drug NCL-240 and the MEK inhibitor cobimetinib against colon carcinoma in vitro
SK Sriraman, V Geraldo, E Luther, A Degterev, V Torchilin
Journal of Controlled Release 220, 160-168, 2015
322015
Drug Delivery to the Central Nervous System
SK Sriraman, G Salzano, V Torchilin
Primer on Cerebrovascular Diseases (Second Edition), 198-201, 2017
42017
Crossing the Endothelial Barrier
B Aryasomayajula, SK Sriraman, VP Torchilin
Drug Delivery Across Physiological Barriers, 209-238, 2016
12016
NANOTHERANOSTICS IN GENE THERAPY
M Deshpande, SK Sriraman, V Torchilin
Nanotheranostics for Personalized Medicine, 191-221, 2016
12016
The system can't perform the operation now. Try again later.
Articles 1–11